NSABP B-42 PUBLICATIONS & ABSTRACTS
Clinical evidence from NSABP B-42
![Extended endocrine publications](https://agendia.com/wp-content/uploads/2024/03/extended-endocrine-publications.webp)
Evidence / Extended Endocrine / NSABP B-42
NSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read MoreB-42 Trial: MammaPrint Utility for Prediction of Extended Letrozole Therapy, ASCO 2021
NSABP B-42 Trial, ASCO 2021 Abstract #502 Authors: Rastogi, et al.
Read More